Ameredes Bill T, Calhoun William J
Am J Respir Crit Care Med. 2006 Nov 1;174(9):965-9; discussion 972-4. doi: 10.1164/rccm.2606001.
Is there scientific evidence to support the replacement of the beta-agonist racemic albuterol with levalbuterol--that is, (R)-albuterol? The argument presented further refines the question as "Do we wish to continue to treat asthma with a mixture of albuterol, of which half is an agent with no known benefit--that is, (S)-albuterol--and which may exacerbate the disease?"
是否有科学证据支持用左旋沙丁胺醇（即 (R)-沙丁胺醇）替代β受体激动剂消旋沙丁胺醇？进一步提出的论点将问题细化为“我们是否希望继续用一种沙丁胺醇混合物来治疗哮喘，其中一半是一种没有已知益处的药物——即 (S)-沙丁胺醇——而且它可能会加重病情？”
